Vergote I - Search Results

1

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Wagner U, et al. Among authors: vergote i. Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26. Br J Cancer. 2012. PMID: 22836511 Free PMC article. Clinical Trial.

2

Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look.

Ramm K, Vergote IB, Kaern J, Tropé CG. Ramm K, et al. Among authors: vergote ib. Gynecol Oncol. 1992 Aug;46(2):203-7. doi: 10.1016/0090-8258(92)90256-i. Gynecol Oncol. 1992. PMID: 1379961

3

Intraperitoneal antineoplastic agents in the management of ovarian cancer.

Tropé C, Kaern J, Vergote I. Tropé C, et al. Among authors: vergote i. Eur J Surg Suppl. 1991 May;(561):83-6. Eur J Surg Suppl. 1991. PMID: 1720054 Review. No abstract available.

4

Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer.

Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjørstad KE, Tropé CG. Vergote IB, et al. Among authors: vergote de vos ln. Cancer. 1992 Feb 1;69(3):741-9. doi: 10.1002/1097-0142(19920201)69:3<741::aid-cncr2820690322>3.0.co;2-g. Cancer. 1992. PMID: 1730124 Clinical Trial.

5

Management of malignant ovarian immature teratoma. Role of adriamycin.

Vergote IB, Abeler VM, Kjørstad KE, Tropé C. Vergote IB, et al. Cancer. 1990 Sep 1;66(5):882-6. doi: 10.1002/1097-0142(19900901)66:5<882::aid-cncr2820660512>3.0.co;2-8. Cancer. 1990. PMID: 2201432 Review.

6

[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer].

Kaern J, Tropé C, Kjørstad KE, Nordal R, Sundfør K, Vergote I, Vossli S, Abeler V, Sandvei R. Kaern J, et al. Among authors: vergote i. Tidsskr Nor Laegeforen. 1990 Sep 10;110(21):2759-62. Tidsskr Nor Laegeforen. 1990. PMID: 2219049 Norwegian.

7

A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas.

Tropé C, Kaern J, Vergote I, Vossli S. Tropé C, et al. Among authors: vergote i. Cancer Chemother Pharmacol. 1990;26 Suppl:S45-7. doi: 10.1007/BF00685418. Cancer Chemother Pharmacol. 1990. PMID: 2347051

8

A randomized trial of adjuvant progestagen in early endometrial cancer.

Vergote I, Kjørstad K, Abeler V, Kolstad P. Vergote I, et al. Cancer. 1989 Sep 1;64(5):1011-6. doi: 10.1002/1097-0142(19890901)64:5<1011::aid-cncr2820640507>3.0.co;2-7. Cancer. 1989. PMID: 2667746 Clinical Trial.

9

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V. Tropé C, et al. Among authors: vergote ib. Gynecol Oncol. 1993 Nov;51(2):236-43. doi: 10.1006/gyno.1993.1279. Gynecol Oncol. 1993. PMID: 8276300 Review.

10

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.

Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Tropé CG. Vergote IB, et al. Am J Obstet Gynecol. 1993 Jul;169(1):40-52. doi: 10.1016/0002-9378(93)90129-7. Am J Obstet Gynecol. 1993. PMID: 8333474

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

870 results

Search Page